A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Communications Biology Année : 2023

A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors

Séverine Tabone-Eglinger
Aroa Soriano
  • Fonction : Auteur
Alberto Villanueva
Stefano Cairo
  • Fonction : Auteur
Pascal Chastagner
  • Fonction : Auteur
Massimo Moro
Cormac Owens
  • Fonction : Auteur
Michela Casanova
  • Fonction : Auteur
Raquel Hladun-Alvaro
  • Fonction : Auteur
Gaelle Pierron

Résumé

Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX models were established following heterotopical and/or orthotopical implantation in immunocompromised mice: 76 sarcomas, 25 other solid tumors, 12 central nervous system tumors, 15 acute leukemias, and 3 lymphomas. PDX establishment rate was 43%. Histology, whole exome and RNA sequencing revealed a high concordance with the primary patient’s tumor profile, human leukocyte-antigen characteristics and specific metabolic pathway signatures. A detailed patient molecular characterization, including specific mutations prioritized in the clinical molecular tumor boards are provided. Ninety models were shared with the IMI2 ITCC Pediatric Preclinical Proof-of-concept Platform (IMI2 ITCC-P4) for further exploitation. This PDX biobank of unique recurrent childhood cancers provides an essential support for basic and translational research and treatments development in advanced pediatric malignancies.
Fichier principal
Vignette du fichier
s42003-023-05320-0.pdf (2.79 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04493070 , version 1 (04-06-2024)

Identifiants

Citer

Maria Eugénia Marques da Costa, Sakina Zaidi, Jean-Yves Scoazec, Robin Droit, Wan Ching Lim, et al.. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors. Communications Biology, 2023, 6 (1), pp.949. ⟨10.1038/s42003-023-05320-0⟩. ⟨hal-04493070⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More